Blueprint Medicines Corp
BPMC129.460USD
0.000
Handelsschluss 10/10, 16:00（ET）Kurse um 15 Minuten verzögert
8.36BMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Blueprint Medicines Corp Unternehmen
Blueprint Medicines Corporation is a global precision therapy company that is inventing life-changing medicines in two areas of allergy/inflammation and oncology/hematology. The Company delivers its approved medicines, including AYVAKIT/AYVAKYT (avapritinib) and GAVRETO (pralsetinib), to patients in the United States and Europe, and it is globally advancing multiple programs for systemic mastocytosis (SM), lung cancer, breast cancer and other genomically defined cancers, and cancer immunotherapy. Its pipelines also include Elenestinib (BLU-263) (KIT), AYVAKIT (avapritinib) (KIT), Wild-type KIT research program, GAVRETO (pralsetinib) (RET), BLU-945 (EGFR), BLU-525 (EGFR), BLU-451 (EGFR exon 20 insertions), BLU-222 (CDK2), AYVAKIT (PDGFRA), GAVRETO (RET), BLU-222 (CDK2) and BLU-852 (MAP4K1). It is developing elenestinib (BLU-263), an investigational, orally available, potent and highly selective KIT inhibitor, for the treatment of indolent SM and other mast cell disorders.
Blueprint Medicines Corp Informationen
BörsenkürzelBPMC
Name des UnternehmensBlueprint Medicines Corp
IPO-datumApr 30, 2015
CEOMs. Kathryn D (Kate) Haviland
Anzahl der mitarbeiter649
WertpapierartOrdinary Share
GeschäftsjahresendeApr 30
Addresse45 Sidney Street
StadtCAMBRIDGE
BörseNASDAQ Global Select Consolidated
LandUnited States of America
Postleitzahl02139
Telefon16173747580
Websitehttps://www.blueprintmedicines.com/
BörsenkürzelBPMC
IPO-datumApr 30, 2015
CEOMs. Kathryn D (Kate) Haviland
Führungskräfte von Blueprint Medicines Corp
Name
Name/Position
Position
Aktienbesitz
Veränderung
Ms. Kathryn D (Kate) Haviland
Ms. Kathryn D (Kate) Haviland
President, Chief Executive Officer
President, Chief Executive Officer
73.23K
+22.22%
Dr. Fouad Namouni, M.D.
Dr. Fouad Namouni, M.D.
President - Research and Development
President - Research and Development
31.96K
+33.54%
Ms. Christina Rossi
Ms. Christina Rossi
Chief Operating Officer
Chief Operating Officer
19.39K
-19.00%
Mr. Percy H. Carter, Ph.D.
Mr. Percy H. Carter, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
16.43K
-13.93%
Mr. Michael Landsittel
Mr. Michael Landsittel
Chief Financial Officer
Chief Financial Officer
13.43K
-68.90%
Ms. Ariel Hurley, CPA
Ms. Ariel Hurley, CPA
Senior Vice President - Finance, Principal Accounting Officer
Senior Vice President - Finance, Principal Accounting Officer
11.89K
--
Mr. Michael J. Tolpa
Mr. Michael J. Tolpa
Director
Director
--
--
Ms. Debra Durso-Bumpus
Ms. Debra Durso-Bumpus
Chief People Officer
Chief People Officer
--
--
Dr. Philina Lee, Ph.D.
Dr. Philina Lee, Ph.D.
Chief Commercial Officer
Chief Commercial Officer
--
-100.00%
Ms. Jenna Cohen
Ms. Jenna Cohen
Vice President and Head, Investor Relations
Vice President and Head, Investor Relations
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Ms. Kathryn D (Kate) Haviland
Ms. Kathryn D (Kate) Haviland
President, Chief Executive Officer
President, Chief Executive Officer
73.23K
+22.22%
Dr. Fouad Namouni, M.D.
Dr. Fouad Namouni, M.D.
President - Research and Development
President - Research and Development
31.96K
+33.54%
Ms. Christina Rossi
Ms. Christina Rossi
Chief Operating Officer
Chief Operating Officer
19.39K
-19.00%
Mr. Percy H. Carter, Ph.D.
Mr. Percy H. Carter, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
16.43K
-13.93%
Mr. Michael Landsittel
Mr. Michael Landsittel
Chief Financial Officer
Chief Financial Officer
13.43K
-68.90%
Ms. Ariel Hurley, CPA
Ms. Ariel Hurley, CPA
Senior Vice President - Finance, Principal Accounting Officer
Senior Vice President - Finance, Principal Accounting Officer
11.89K
--
Umsatzaufteilung
Währung: USDAktualisiert: Sun, Apr 6
Währung: USDAktualisiert: Sun, Apr 6
FY2024Q3
FY2024Q2
FY2024Q1
Nach GeschäftsbereichUSD
Name
Umsatz
Anteil
Product revenue
128.18M
100.00%
Collaboration, license and other revenue
1.00K
0.00%
Nach RegionUSD
Name
Umsatz
Anteil
United States
113.13M
88.26%
Rest of the world
15.05M
11.74%
Nach Geschäftsbereich
Nach Region
Nach GeschäftsbereichUSD
Name
Umsatz
Anteil
Product revenue
128.18M
100.00%
Collaboration, license and other revenue
1.00K
0.00%
Aktionärsstatistik
Aktualisiert: Wed, Aug 13
Aktualisiert: Wed, Aug 13
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
The Vanguard Group, Inc.
9.90%
T. Rowe Price Associates, Inc.
8.28%
BlackRock Institutional Trust Company, N.A.
7.29%
Avoro Capital Advisors LLC
5.95%
Wellington Management Company, LLP
4.75%
Andere
63.83%
Aktionäre
Aktionäre
Anteil
The Vanguard Group, Inc.
9.90%
T. Rowe Price Associates, Inc.
8.28%
BlackRock Institutional Trust Company, N.A.
7.29%
Avoro Capital Advisors LLC
5.95%
Wellington Management Company, LLP
4.75%
Andere
63.83%
Aktionärstypen
Aktionäre
Anteil
Investment Advisor
42.13%
Hedge Fund
26.61%
Investment Advisor/Hedge Fund
24.80%
Research Firm
3.16%
Sovereign Wealth Fund
1.66%
Individual Investor
0.93%
Bank and Trust
0.78%
Pension Fund
0.78%
Venture Capital
0.41%
Institutionelle Beteiligung
Aktualisiert: Tue, Jul 1
Aktualisiert: Tue, Jul 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q2
701
68.81M
106.41%
-3.22M
2025Q1
702
71.75M
110.98%
-1.27M
2024Q4
657
69.17M
108.25%
-2.83M
2024Q3
644
67.12M
105.97%
-7.85M
2024Q2
622
68.23M
108.95%
-6.94M
2024Q1
615
67.81M
110.73%
-5.62M
2023Q4
612
65.87M
108.35%
-10.02M
2023Q3
602
66.47M
109.56%
-7.64M
2023Q2
614
65.78M
108.78%
-8.60M
2023Q1
625
65.63M
109.42%
-10.28M
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
The Vanguard Group, Inc.
--
0%
-223.92K
-100.00%
T. Rowe Price Associates, Inc.
--
0%
-3.95M
-100.00%
BlackRock Institutional Trust Company, N.A.
--
0%
-182.70K
-100.00%
State Street Global Advisors (US)
--
0%
-453.14K
-100.00%
Geode Capital Management, L.L.C.
--
0%
+18.37K
-100.00%
Macquarie Investment Management
--
0%
-364.73K
-100.00%
AllianceBernstein L.P.
--
0%
-430.85K
-100.00%
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Wed, Aug 6
Aktualisiert: Wed, Aug 6
Name
Anteil
ProShares Merger ETF
3.21%
AltShares Event-Driven ETF
1.43%
ProShares Ultra Nasdaq Biotechnology
0.92%
Goldman Sachs Future Health Care Equity ETF
0.84%
Hypatia Women CEO ETF
0.73%
First Trust Mid Cap Growth AlphaDEX Fund
0.58%
iShares Russell 2000 Growth ETF
0.54%
WisdomTree BioRevolution Fund
0.49%
SoFi Next 500 ETF
0.45%
JPMorgan Fundamental Data Science Small Core ETF
0.43%
Mehr Anzeigen
ProShares Merger ETF
Anteil3.21%
AltShares Event-Driven ETF
Anteil1.43%
ProShares Ultra Nasdaq Biotechnology
Anteil0.92%
Goldman Sachs Future Health Care Equity ETF
Anteil0.84%
Hypatia Women CEO ETF
Anteil0.73%
First Trust Mid Cap Growth AlphaDEX Fund
Anteil0.58%
iShares Russell 2000 Growth ETF
Anteil0.54%
WisdomTree BioRevolution Fund
Anteil0.49%
SoFi Next 500 ETF
Anteil0.45%
JPMorgan Fundamental Data Science Small Core ETF
Anteil0.43%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
Keine Daten
Datum
Art
Verhältnis
Keine Daten
